SCHEMBL16835992

SCHEMBL16835992

CC1(C)OC2(CCNCC2)c2cccnc21

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AVPR1A P37288 8/20 0.48
SIGMAR1 Q99720 2/20 0.37
ALDH1A1 P00352 4/20 0.34
HSD17B10 Q99714 4/20 0.34
HPGD P15428 3/20 0.34
CYP1A2 P05177 2/20 0.34
OPRM1 P35372 1/20 0.34
CYP3A4 P08684 3/20 0.33
CYP2D6 P10635 3/20 0.33
TSHR P16473 3/20 0.33
USP2 O75604 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
MEN1 O00255 1/20 0.33
MAPK1 P28482 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
AKR1B1 P15121 1/20 0.31
PDK2 Q15119 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL25234967 0.98 AVPR1A (0.47) AVPR1ASIGMAR1ALDH1A1HSD17B10HPGD
Hydrochloric Acid SCHEMBL30360567 0.98 AVPR1A (0.47) AVPR1ASIGMAR1ALDH1A1HSD17B10HPGD
SCHEMBL16835918 0.88 AVPR1A (0.48) AVPR1ASIGMAR1ALDH1A1HSD17B10HPGD
SCHEMBL738649 0.79 SIGMAR1 (0.46) AVPR1ASIGMAR1OPRM1CYP2D6TSHR
SCHEMBL16835951 0.75 AVPR1A (0.53) AVPR1AALDH1A1HSD17B10HPGDMEN1
SCHEMBL23508738 0.71 ALDH1A1 (0.38) SIGMAR1ALDH1A1HSD17B10HPGDCYP1A2
SCHEMBL16844856 0.70 AVPR1A (0.48) AVPR1ATSHRPDK2
SCHEMBL27628449 0.69 ALDH1A1 (0.39) ALDH1A1HSD17B10HPGDCYP1A2OPRM1
SCHEMBL25358499 0.69 OPRM1 (0.36) AVPR1ASIGMAR1OPRM1MEN1KMT2A
SCHEMBL2515629 0.69 AVPR1A (0.46) AVPR1ASIGMAR1ALDH1A1HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066378-A1 SPIRO-OXAZOLONES HOFFMANN-LA ROCHE INC. (US) 2025-02-27 US disclosed
US-12162887-B2 Spiro-oxazolones HOFFMANN-LA ROCHE INC. (US) 2024-12-10 US disclosed
WO-2023088996-A1 SYNTHESIS OF 2'-(7,7-DIMETHYL-1'H,7H-SPIRO[FURO[3,4-B]PYRIDINE-5,4'-PIPERIDIN]-1'-YL)-1,3-DIHYDRO-4'H-SPIRO[INDENE-2,5'-[1,3]OXAZOL]-4'-ONE, AND CRYSTALLINE FORMS THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2023-05-25 WO disclosed
US-20230106150-A1 SPIRO-OXAZOLONES HOFFMANN-LA ROCHE INC. (US) 2023-04-06 US disclosed
US-11578077-B2 Spiro-oxazolones HOFFMANN-LA ROCHE INC. (US) 2023-02-14 US disclosed
US-11578077-B2 Spiro-oxazolones HOFFMANN-LA ROCHE INC. (US) 2023-02-14 US disclosed
US-20200039997-A1 SPIRO-OXAZOLONES HOFFMANN-LA ROCHE INC. (US) 2020-02-06 US disclosed
US-20200039997-A1 SPIRO-OXAZOLONES HOFFMANN-LA ROCHE INC. (US) 2020-02-06 US disclosed
US-10479796-B2 Spiro-oxazolones HOFFMAN-LA ROCHE INC. (US) 2019-11-19 US disclosed
US-10479796-B2 Spiro-oxazolones HOFFMAN-LA ROCHE INC. (US) 2019-11-19 US disclosed
EP-3083633-B1 SPIRO-OXAZOLONES HOFFMANN LA ROCHE (CH) 2017-11-29 EP disclosed
EP-3083633-B1 SPIRO-OXAZOLONES HOFFMANN LA ROCHE (CH) 2017-11-29 EP disclosed
US-20170008901-A1 SPIRO-OXAZOLONES HOFFMANN-LA ROCHE INC. (US) 2017-01-12 US disclosed
US-20170008901-A1 SPIRO-OXAZOLONES HOFFMANN-LA ROCHE INC. (US) 2017-01-12 US disclosed
US-20170008901-A1 SPIRO-OXAZOLONES HOFFMANN-LA ROCHE INC. (US) 2017-01-12 US disclosed
EP-3083633-A1 SPIRO-OXAZOLONES F.HOFFMANN-LA ROCHE AG (CH) 2016-10-26 EP disclosed
WO-2015091411-A1 SPIRO-OXAZOLONES F. HOFFMANN-LA ROCHE AG (CH) 2015-06-25 WO disclosed
WO-2015091411-A1 SPIRO-OXAZOLONES F. HOFFMANN-LA ROCHE AG (CH) 2015-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162887-B2 Spiro-oxazolones AVPR1A, AVPR1B, AVPR2 AVPR1A 1/4885SIGMAR1 178/4885ALDH1A1 1228/4885
US-11578077-B2 Spiro-oxazolones AVPR1A, AVPR1B, AVPR2 AVPR1A 1/4885SIGMAR1 178/4885ALDH1A1 1228/4885
US-20250066378-A1 SPIRO-OXAZOLONES AVPR1A, AVPR1B, AVPR2 AVPR1A 1/4885SIGMAR1 178/4885ALDH1A1 1228/4885
US-20200039997-A1 SPIRO-OXAZOLONES AVPR1A, AVPR1B, AVPR2 AVPR1A 1/4885SIGMAR1 178/4885ALDH1A1 1228/4885
US-20170008901-A1 SPIRO-OXAZOLONES AVPR1A, AVPR1B, AVPR2 AVPR1A 1/4885SIGMAR1 178/4885ALDH1A1 1228/4885
US-20230106150-A1 SPIRO-OXAZOLONES AVPR1A, AVPR1B, AVPR2 AVPR1A 1/4885SIGMAR1 178/4885ALDH1A1 1228/4885
US-10479796-B2 Spiro-oxazolones AVPR1A, AVPR1B, AVPR2 AVPR1A 1/4885SIGMAR1 178/4885ALDH1A1 1228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.